. "Appendix D-7: The Prospects for Immunizing Against Mycobacterium leprae." New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press, 1986.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
New Vaccine Development: Establishing Priorities, Volume II, Diseases of Importance in Developing Countries
Problems to be Overcome
Major economic, political, and social problems may hamper efforts to evaluate potential vaccine candidates for leprosy. Research and field studies to determine which vaccines are most appropriate for specific populations will be expensive. Some areas of the developing world that possess the field and clinical expertise to participate in vaccine trials and evaluations lack the national political commitment to initiate and carry out essential background work. The most significant social question will be whether the identification of an effective vaccine for leprosy and the development of suitable delivery systems can overcome the universal stigma associated with the disease.
Bloom, B.R. 1985. Personal communication, Albert Einstein College of Medicine, Bronx, N.Y.
Bloom, B.R., and T.Godal. 1983. Selective primary health care: strategies for control of disease in the developing world. V. Leprosy. Rev. Infect. Dis. 5(4):765–780.
Bloom, B.R., and V.Mehra. 1984. Vaccine strategies for the eradication of leprosy. Pp. 368–389 in New Approaches to Vaccine Development, R.Bell and G.Torrigiani, eds. Basel, Switzerland: Schwabe and Co. AG.
Convit, J., M.Aranzazu, M.Pinardi, and M.Ulrich. 1979. Immunological changes observed in indeterminate and lepromatous leprosy patients and Mitsuda-negative contacts after the inoculation of a mixture of Mycobacterium leprae and BCG. Clin. Exp. Immuno. 36:214,
Convit, J., M.Aranzazu, M.Ulrich, M.Zuniga, M.E. De Aragon, J.Alvarado, and O.Reyes. 1983. Investigations related to the development of a leprosy vaccine. Int. J. Lepr. 51:531–539.
Deo, M.G., C.V.Bapt, V.Bhalerao, R.M.Chaturvedi, W.S.Bhatki, and R.G.Chulawala. 1983. Antileprosy potential of ICRC vaccine: A study in patients and healthy volunteers. Int. J.Lepr. 51:540–549.
Fine, P.E.M. 1982. Leprosy: The epidemiology of a slow bacterium. Epidemiol. Rev. 4:161–188.
Fine, P.E.M. 1985. The role of BCG in the control of leprosy. The Kellersberger Memorial Lecture. Ethiopian Med. J. 23:179–188.
Gill, H.K., A.S.Mustafa, and T.Godal. In press. Sensitization of normal human volunteers with a candidate vaccine against leprosy. Bull. WHO.
Irgens, L.M. 1980. Leprosy in Norway. An epidemiological study based on a national patient registry. Lepr. Rev. 51(suppl. 1): 1–130.
Mehra, V., and B.R.Bloom. 1979. Induction of cell mediated immunity to Mycobacterium leprae in guinea pigs. Infect. Immun. 23:787–794.
Noordeen, S.K. 1984. Personal communication, World Health Organization, Geneva.
Samuel, N.M., K.Neupani, R.J.W.Rees, J.L.Stanford, and R.B.Adiga. 1984. Vaccination of contacts, normals, and leprosy patients.